East Genomics
-
The role of genomics in midwifery
Angela Crosby, Antenatal and Newborn Screening Coordinator, United Lincolnshire Hospitals NHS Trust (ULHT), talks about the role of her team and the impact genomics has in their work.
Read more
-
The importance of identifying patients with Monogenic Diabetes
Anita Murphy, regional Genetic Diabetes Nurse, highlights why this type of diabetes should be considered when patients are seen.
Find out more
-
More than 100 children with cancer across the East of England benefit from whole genome sequencing
Read more
-
The importance of identifying patients with Monogenic Diabetes
For Diabetes Week (13 - 19 June), Anita Murphy, our regional Genetic Diabetes Nurse - East Midlands and East of England - has shared with us why it is important for clinicians to consider this type of diabetes when seeing patients and how it can change th
-
Nursing and midwifery team appointed to help peers across the region take a proactive role in genomic medicine
The recently appointed nursing and midwifery staff at East Genomics are an essential part of the strategic team to support the mainstreaming of genomic medicine into clinical practice across the East of England and East Midlands to help improve patient care and outcomes.
-
More than 100 children with cancer across the East of England benefit from whole genome sequencing
In a significant milestone, more than 100 children with cancer from across the East of England have had their tumours tested by whole genome sequencing (WGS) and interpreted by scientists in the NHS Genomic Medicine Service at Cambridge University Hospitals NHS Foundation Trust (CUH), to help improve their diagnosis and treatment.
-
Largest study of whole genome sequencing data reveals new causes of cancer
Cambridge analysis of more than 12,000 tumours from NHS patients has found DNA evidence of over 50 new potential causes of cancer.
-
Revolutionary new treatment path for patients with aggressive brain tumours
Brain tumour patients at Addenbrooke’s Hospital in Cambridge are the first in the UK to benefit from personalised treatment using the latest advances in genomics and targeted therapies through the Minderoo Foundation's new Precision Brain Tumour Programme (MPBTP).